Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors

Affiliations

• ¹ Institut Curie, Paris.
• ² Maria Sklodowska-Curie National Research Institute of Oncology, Krakow.
• ³ Plymouth University Medical School, Plymouth, UK; AstraZeneca, Mississauga, Ontario.
• ⁴ IRCCS Azienda Ospedaliero- Universitaria di Bologna Istituto di Ematologia "Seràgnoli"; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna, Bologna.
• ⁵ John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ.
• ⁶ University of Washington, Fred Hutchinson Cancer Center, Seattle, WA.
• ⁷ Erasmus MC Cancer Institute, on behalf of the HOVON Lunenburg Lymphoma Phase I/II Consortium, Rotterdam.
• ⁸ Hospital Universitario Donostia, San Sebastián.
• ⁹ Moffitt Cancer Center, Tampa, FL.
• ¹⁰ NIHR/Cancer Research UK Experimental Cancer Medicines Centre, University of Southampton Faculty of Medicine, Southampton.
• ¹¹ Border Medical Oncology, Albury, NSW.
• ¹² Dana Farber Cancer Institute, Harvard Medical School, Boston, MA.
• ¹³ Amsterdam University Medical Center, Amsterdam, on behalf of the HOVON Lunenburg Lymphoma Phase I/II Consortium.
• ¹⁴ Copernicus Memorial Hospital, Medical University of Lodz, Lodz.
• ¹⁵ MD Anderson Cancer Center, University of Texas, Houston, TX.
• ¹⁶ AstraZeneca, Gaithersburg, MD.
• ¹⁷ AstraZeneca, South San Francisco, CA.
• ¹⁸ MD Anderson Cancer Center, University of Texas, Houston, TX. miwang@mdanderson.org.